Centogene BV filed to sell 4 million common shares on Nasdaq for between $14 and $16 in an IPO expected to raise $60 million at the midpoint.

“We’re in a global market. We need to stop being parochial and work globally from the beginning.”

The FDA’s Janet Woodcock, director of the Center for Drug Evaluation and Research, testified before a House subcommittee on the national security risk raised by U.S. reliance on China exports of active pharmaceutical ingredients (API).

Biotech money raised to-date and by month in 2019, including public, private and other financings.

Follow-ons completed by biopharma companies in October 2019.

Completed and pending initial public offerings by biopharma companies in October 2019.

Private placements and other private financings of public biopharma companies in October 2019.

Venture capital and other private financings of private biopharma companies in October 2019.

Triggered milestone payments disclosed by biopharma companies in October 2019.

These graphs compare the performance of the biotech stocks for all of 2019 using the BioWorld Stock Indicator and the Nasdaq Biotech Index.